Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
98.41
-3.03 (-2.99%)
May 8, 2025, 4:00 PM - Market closed
Jazz Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 4,065 | 4,069 | 3,834 | 3,659 | 3,094 | 2,364 | Upgrade
|
| Revenue Growth (YoY) | 5.76% | 6.12% | 4.78% | 18.26% | 30.91% | 9.34% | Upgrade
|
| Cost of Revenue | 318.9 | 310.7 | 284.13 | 267.13 | 217.68 | 148.92 | Upgrade
|
| Gross Profit | 3,746 | 3,758 | 3,550 | 3,392 | 2,877 | 2,215 | Upgrade
|
| Selling, General & Admin | 1,578 | 1,416 | 1,307 | 1,399 | 1,399 | 879.85 | Upgrade
|
| Research & Development | 811.37 | 853.56 | 823.89 | 555.41 | 476.33 | 309.76 | Upgrade
|
| Operating Expenses | 3,015 | 2,897 | 2,739 | 2,553 | 2,401 | 1,449 | Upgrade
|
| Operating Income | 730.48 | 861.64 | 810.73 | 839.14 | 475.26 | 765.46 | Upgrade
|
| Interest Expense | -331.99 | -344.4 | -354.54 | -299.74 | -280.57 | -110.81 | Upgrade
|
| Interest & Investment Income | 106.3 | 106.3 | 65.1 | 11.5 | 1.8 | 11.1 | Upgrade
|
| Earnings From Equity Investments | -0.86 | -1.66 | -3.01 | -9.92 | -0.71 | -2.96 | Upgrade
|
| Currency Exchange Gain (Loss) | -6.7 | -8.18 | 8.79 | -19.01 | -4.35 | -3.27 | Upgrade
|
| EBT Excluding Unusual Items | 497.24 | 613.71 | 527.07 | 521.97 | 191.43 | 659.52 | Upgrade
|
| Merger & Restructuring Charges | -135.95 | -135.01 | -151.45 | -326.88 | -304.99 | - | Upgrade
|
| Asset Writedown | - | - | -61.7 | -133.65 | - | -136.14 | Upgrade
|
| Pretax Income | 361.29 | 468.69 | 294.92 | -382.71 | -113.55 | 272.13 | Upgrade
|
| Income Tax Expense | -120.91 | -91.43 | -119.91 | -158.65 | 216.12 | 33.52 | Upgrade
|
| Earnings From Continuing Operations | 482.2 | 560.12 | 414.83 | -224.06 | -329.67 | 238.62 | Upgrade
|
| Net Income | 482.2 | 560.12 | 414.83 | -224.06 | -329.67 | 238.62 | Upgrade
|
| Net Income to Common | 482.2 | 560.12 | 414.83 | -224.06 | -329.67 | 238.62 | Upgrade
|
| Net Income Growth | 45.77% | 35.02% | - | - | - | -54.41% | Upgrade
|
| Shares Outstanding (Basic) | 61 | 62 | 63 | 63 | 60 | 56 | Upgrade
|
| Shares Outstanding (Diluted) | 66 | 66 | 72 | 63 | 60 | 57 | Upgrade
|
| Shares Change (YoY) | -5.26% | -8.41% | 15.23% | 4.77% | 5.62% | -1.80% | Upgrade
|
| EPS (Basic) | 7.85 | 9.06 | 6.55 | -3.58 | -5.52 | 4.28 | Upgrade
|
| EPS (Diluted) | 7.51 | 8.65 | 6.10 | -3.58 | -5.52 | 4.22 | Upgrade
|
| EPS Growth | 49.21% | 41.75% | - | - | - | -53.57% | Upgrade
|
| Free Cash Flow | 1,513 | 1,358 | 1,068 | 1,243 | 750.87 | 884.64 | Upgrade
|
| Free Cash Flow Per Share | 23.06 | 20.57 | 14.82 | 19.87 | 12.58 | 15.65 | Upgrade
|
| Gross Margin | 92.16% | 92.36% | 92.59% | 92.70% | 92.97% | 93.70% | Upgrade
|
| Operating Margin | 17.97% | 21.18% | 21.14% | 22.93% | 15.36% | 32.39% | Upgrade
|
| Profit Margin | 11.86% | 13.77% | 10.82% | -6.12% | -10.65% | 10.10% | Upgrade
|
| Free Cash Flow Margin | 37.23% | 33.37% | 27.86% | 33.97% | 24.27% | 37.43% | Upgrade
|
| EBITDA | 1,392 | 1,522 | 1,449 | 1,469 | 1,028 | 1,044 | Upgrade
|
| EBITDA Margin | 34.25% | 37.40% | 37.80% | 40.13% | 33.22% | 44.16% | Upgrade
|
| D&A For EBITDA | 661.56 | 660.07 | 638.7 | 629.47 | 552.48 | 278.25 | Upgrade
|
| EBIT | 730.48 | 861.64 | 810.73 | 839.14 | 475.26 | 765.46 | Upgrade
|
| EBIT Margin | 17.97% | 21.18% | 21.14% | 22.93% | 15.36% | 32.39% | Upgrade
|
| Effective Tax Rate | - | - | - | - | - | 12.32% | Upgrade
|
| Revenue as Reported | 4,065 | 4,069 | 3,834 | 3,659 | 3,094 | 2,364 | Upgrade
|
| Advertising Expenses | - | 107.4 | 92.2 | 108.8 | 161.5 | 99.6 | Upgrade
|
Updated May 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.